Equities

Hepion Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Hepion Pharmaceuticals Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.5465
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-16.44m
  • Incorporated2013
  • Employees22.00
  • Location
    Hepion Pharmaceuticals Inc399 Thornall StEDISON 08837-2236United StatesUSA
  • Phone+1 (732) 902-4000
  • Fax+1 (732) 902-4100
  • Websitehttps://hepionpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.